Curis, Inc. (CRIS) 10-Year Financial Performance & Capital Metrics

CRIS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Show more

Revenue $11M +8.8%
EBITDA -$44M +7.8%
Net Income -$43M +8.5%
EPS (Diluted) -6.88 +23.2%
Gross Margin 99.1% +1.2%
EBITDA Margin -406.48% +15.3%
Operating Margin -408.34% +15.3%
Net Margin -397.77% +15.9%
ROE -634.71% -343.3%
ROIC -
Debt/Equity -
Interest Coverage -72.43 -202.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 19.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.03%

5Y1.75%

3Y0.8%

TTM13.56%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM53.07%

ROCE

10Y Avg-66.65%

5Y Avg-53.47%

3Y Avg-73.5%

Latest-114.95%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.88M	7.53M	9.9M	10.43M	10M	10.84M	10.65M	10.16M	10.02M	10.91M
Revenue Growth %	-0.2%	-0.04%	0.31%	0.05%	-0.04%	0.08%	-0.02%	-0.05%	-0.01%	0.09%
Cost of Goods Sold+	405.76K	399K	496K	563K	503K	534K	533K	257K	212K	98K
COGS % of Revenue	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%	0.03%	0.02%	0.01%
Gross Profit+	7.47M	7.13M	9.4M	9.87M	9.5M	10.3M	10.12M	9.9M	9.81M	10.81M
Gross Margin %	0.95%	0.95%	0.95%	0.95%	0.95%	0.95%	0.95%	0.97%	0.98%	0.99%
Gross Profit Growth %	-0.21%	-0.05%	0.32%	0.05%	-0.04%	0.08%	-0.02%	-0.02%	-0.01%	0.1%
Operating Expenses+	39.61M	47.18M	59.16M	39.2M	33.86M	35.2M	52.18M	62.92M	58.14M	55.35M
OpEx % of Revenue	5.03%	6.27%	5.98%	3.76%	3.38%	3.25%	4.9%	6.19%	5.8%	5.07%
Selling, General & Admin	12.91M	15.59M	25.82M	14.79M	11.55M	12.13M	17.3M	19.65M	18.65M	16.79M
SG&A % of Revenue	1.64%	2.07%	2.61%	1.42%	1.16%	1.12%	1.62%	1.93%	1.86%	1.54%
Research & Development	26.7M	31.59M	33.34M	24.41M	22.3M	23.07M	34.88M	43.28M	39.5M	38.56M
R&D % of Revenue	3.39%	4.2%	3.37%	2.34%	2.23%	2.13%	3.28%	4.26%	3.94%	3.54%
Other Operating Expenses	0	-1K	-104K	0	0	0	0	0	0	0
Operating Income+	-56.48M	-58.04M	-49.76M	-29.33M	-24.36M	-24.9M	-42.06M	-53.02M	-48.33M	-44.54M
Operating Margin %	-7.17%	-7.71%	-5.03%	-2.81%	-2.43%	-2.3%	-3.95%	-5.22%	-4.82%	-4.08%
Operating Income Growth %	-2.56%	-0.03%	0.14%	0.41%	0.17%	-0.02%	-0.69%	-0.26%	0.09%	0.08%
EBITDA+	-56.32M	-57.85M	-49.52M	-29.16M	-24.23M	-24.75M	-41.91M	-52.79M	-48.08M	-44.34M
EBITDA Margin %	-7.15%	-7.69%	-5%	-2.8%	-2.42%	-2.28%	-3.94%	-5.19%	-4.8%	-4.06%
EBITDA Growth %	-2.59%	-0.03%	0.14%	0.41%	0.17%	-0.02%	-0.69%	-0.26%	0.09%	0.08%
D&A (Non-Cash Add-back)	160.81K	193K	235K	177K	125K	144K	158K	233K	255K	203K
EBIT	-55.66M	-57.63M	-49.35M	-28.65M	-27.3M	-24.81M	-40.96M	-51.9M	-45.39M	-42.77M
Net Interest Income+	-3.05M	-2.37M	-3.45M	-3.24M	-4.23M	-5.03M	-4.26M	-3.65M	919K	1.15M
Interest Income	824.85K	405K	513K	684K	614K	63K	211K	1.12M	2.94M	1.77M
Interest Expense	3.33M	2.78M	3.97M	3.93M	4.85M	5.09M	4.47M	4.77M	2.02M	615K
Other Income/Expense	-26.85M	-2.37M	-3.56M	-3.24M	-7.79M	-5.01M	-3.37M	-3.65M	919K	1.15M
Pretax Income+	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Pretax Margin %	-7.49%	-8.03%	-5.39%	-3.12%	-3.21%	-2.76%	-4.27%	-5.58%	-4.73%	-3.98%
Income Tax+	3.16M	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Net Margin %	-7.49%	-8.03%	-5.39%	-3.12%	-3.21%	-2.76%	-4.27%	-5.58%	-4.73%	-3.98%
Net Income Growth %	-2.15%	-0.02%	0.12%	0.39%	0.01%	0.07%	-0.52%	-0.25%	0.16%	0.08%
Net Income (Continuing)	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-47.81	-45.50	-35.75	-19.67	-19.37	-12.29	-9.92	-12.14	-8.96	-6.88
EPS Growth %	-1.2%	0.05%	0.21%	0.45%	0.02%	0.37%	0.19%	-0.22%	0.26%	0.23%
EPS (Basic)	-47.81	-45.50	-35.75	-19.67	-19.37	-12.29	-9.92	-12.14	-8.96	-6.88
Diluted Shares Outstanding	1.23M	1.33M	1.49M	1.66M	1.66M	2.43M	4.58M	4.67M	5.29M	6.31M
Basic Shares Outstanding	1.23M	1.33M	1.49M	1.66M	1.66M	2.43M	4.58M	4.67M	5.29M	6.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	84.3M	46.94M	64.29M	27.13M	25M	172.75M	122.38M	92.12M	60.91M	26.39M
Cash & Short-Term Investments	82.19M	44.48M	60.23M	24.27M	20.54M	168.49M	115.88M	85.62M	56.33M	20M
Cash Only	33.09M	26.04M	38.29M	23.64M	15.43M	129.61M	40.01M	19.66M	26.68M	20M
Short-Term Investments	49.1M	18.45M	21.94M	634K	5.11M	38.88M	75.87M	65.97M	29.65M	0
Accounts Receivable	2.11M	2.46M	3.07M	2.86M	3.24M	3.04M	3.22M	2.98M	2.79M	3.35M
Days Sales Outstanding	97.57	119.24	113.32	100.25	118.36	102.51	110.5	106.86	101.75	112.06
Inventory	-1.2M	-1.26M	0	-827K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	153K	0	0	3.52M	1.78M	3.04M
Total Non-Current Assets+	10.67M	10.81M	9.5M	10.23M	10.1M	31.61M	39.93M	16.73M	16.37M	14.88M
Property, Plant & Equipment	277.71K	413K	366K	267K	303K	7.24M	6.25M	5.09M	3.49M	3.39M
Fixed Asset Turnover	28.37x	18.23x	27.04x	39.06x	33.02x	1.50x	1.70x	2.00x	2.87x	3.21x
Goodwill	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	152.61K	153K	153K	153K	0	14.56M	23.96M	0	0	544K
Other Non-Current Assets	1.41M	1.41M	156K	982K	819K	819K	726K	2.66M	3.9M	1.96M
Total Assets+	94.97M	57.75M	73.8M	37.37M	35.11M	204.36M	162.3M	108.85M	77.28M	41.27M
Asset Turnover	0.08x	0.13x	0.13x	0.28x	0.28x	0.05x	0.07x	0.09x	0.13x	0.26x
Asset Growth %	0.52%	-0.39%	0.28%	-0.49%	-0.06%	4.82%	-0.21%	-0.33%	-0.29%	-0.47%
Total Current Liabilities+	6.29M	8.63M	14.1M	6.38M	6.54M	10.08M	13.44M	10.01M	22.02M	19.03M
Accounts Payable	4.22M	5.88M	5.42M	2.91M	4.46M	4.17M	6.42M	3.19M	3.17M	3.02M
Days Payables Outstanding	3.79K	5.38K	3.99K	1.89K	3.24K	2.85K	4.39K	4.53K	5.46K	11.26K
Short-Term Debt	4.61M	4.94M	5.89M	6.88M	0	557K	0	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	-3.16M	2.03M	606K	683K	1.41M	2.64M	3.26M	0	8.5M	7.56M
Current Ratio	13.40x	5.44x	4.56x	4.25x	3.82x	17.14x	9.11x	9.20x	2.77x	1.39x
Quick Ratio	13.59x	5.59x	4.56x	4.38x	3.82x	17.14x	9.11x	9.20x	2.77x	1.39x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	24.16M	19.86M	35.7M	35.48M	62.48M	63.61M	58.16M	52.28M	35.59M	28.24M
Long-Term Debt	19.56M	14.92M	35.67M	28.6M	0	334K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	5.04M	4.36M	2.8M	1.49M	1.62M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.61M	18K	34K	11K	62.48M	58.23M	53.8M	49.48M	34.1M	26.62M
Total Liabilities	30.45M	28.49M	49.8M	41.86M	69.02M	73.69M	71.59M	62.3M	57.61M	47.26M
Total Debt+	24.16M	19.86M	41.55M	35.48M	166K	7.66M	5.04M	3.94M	2.79M	2.95M
Net Debt	-8.93M	-6.18M	3.27M	11.85M	-15.26M	-121.95M	-34.97M	-15.72M	-23.89M	-17.04M
Debt / Equity	0.37x	0.68x	1.73x	-	-	0.06x	0.06x	0.08x	0.14x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.99x	-20.90x	-12.55x	-7.47x	-5.03x	-4.89x	-9.41x	-11.11x	-23.94x	-72.43x
Total Equity+	64.51M	29.27M	23.99M	-4.5M	-33.91M	130.67M	90.71M	46.55M	19.67M	-6M
Equity Growth %	1.17%	-0.55%	-0.18%	-1.19%	-6.54%	4.85%	-0.31%	-0.49%	-0.58%	-1.3%
Book Value per Share	52.29	22.04	16.09	-2.72	-20.44	53.70	19.81	9.97	3.72	-0.95
Total Shareholders' Equity	64.51M	29.27M	23.99M	-4.5M	-33.91M	130.67M	90.71M	46.55M	19.67M	-6M
Common Stock	1.3M	1.42M	1.65M	332K	332K	915K	916K	48K	59K	85K
Retained Earnings	-838.54M	-898.95M	-952.26M	-984.84M	-1.02B	-1.05B	-1.09B	-1.15B	-1.2B	-1.24B
Treasury Stock	-1.52M	-1.52M	-1.52M	0	0	0	0	0	0	0
Accumulated OCI	27.77K	-4K	-2K	0	0	-3K	-109K	-186K	229K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.89M	-35.81M	-48.35M	-30.07M	-26.2M	-25.74M	-37.62M	-54.34M	-38.43M	-39.56M
Operating CF Margin %	-3.79%	-4.76%	-4.89%	-2.88%	-2.62%	-2.38%	-3.53%	-5.35%	-3.83%	-3.63%
Operating CF Growth %	-0.78%	-0.2%	-0.35%	0.38%	0.13%	0.02%	-0.46%	-0.44%	0.29%	-0.03%
Net Income	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Depreciation & Amortization	160.81K	193K	235K	177K	125K	144K	158K	1.39M	255K	187K
Stock-Based Compensation	3.88M	4.33M	5.36M	3.94M	0	2.7M	5.28M	0	6M	5.93M
Deferred Taxes	-21.55K	0	0	7K	0	24K	1.4M	0	0	0
Other Non-Cash Items	24.17M	18.2M	91K	-112K	7.37M	255K	-26K	7.76M	-55K	1.43M
Working Capital Changes	903.59K	1.88M	-723K	-1.5M	-1.56M	1.05M	1M	-6.82M	2.78M	-3.72M
Change in Receivables	-145.04K	-353K	-614K	209K	-380K	201K	-181K	249K	181K	-555K
Change in Inventory	-75.47M	-34.74M	-49.92M	1.87M	0	0	0	0	0	0
Change in Payables	1.77M	2.31M	-376K	-1.87M	60K	1M	4.96M	-3.88M	3.34M	-2.08M
Cash from Investing+	-6.43M	30.12M	-3.63M	21.37M	-4.46M	-49.05M	-47.9M	33.02M	37.79M	29.44M
Capital Expenditures	-47.98K	-329K	-188K	-85K	-41K	-677K	0	-416K	0	0
CapEx % of Revenue	0.01%	0.04%	0.02%	0.01%	0%	0.06%	-	0.04%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	13.88K	-329K	-188K	-85K	0	0	0	0	0	0
Cash from Financing+	61.66M	-1.37M	64.23M	-5.96M	23.27M	188.81M	-4.17M	867K	7.58M	3.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	946K	143K	0	-5.3M	-4.47M	0	-6.54M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-29.94M	-36.14M	-48.54M	-30.15M	-26.25M	-26.42M	-37.62M	-54.75M	-38.43M	-39.56M
FCF Margin %	-3.8%	-4.8%	-4.9%	-2.89%	-2.62%	-2.44%	-3.53%	-5.39%	-3.83%	-3.63%
FCF Growth %	-0.77%	-0.21%	-0.34%	0.38%	0.13%	-0.01%	-0.42%	-0.46%	0.3%	-0.03%
FCF per Share	-24.27	-27.22	-32.55	-18.21	-15.82	-10.86	-8.22	-11.73	-7.26	-6.27
FCF Conversion (FCF/Net Income)	0.51x	0.59x	0.91x	0.92x	0.82x	0.86x	0.83x	0.96x	0.81x	0.91x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-125.1%	-128.84%	-200.22%	-334.15%	-	-61.82%	-41.05%	-82.58%	-143.19%	-634.71%
Return on Invested Capital (ROIC)	-79.99%	-110.66%	-148.25%	-127.12%	-	-	-97.89%	-91.87%	-272.36%	-
Gross Margin	94.85%	94.7%	94.99%	94.6%	94.97%	95.07%	94.99%	97.47%	97.88%	99.1%
Net Margin	-748.64%	-802.59%	-538.66%	-312.38%	-321.28%	-276.03%	-426.67%	-557.69%	-473.04%	-397.77%
Debt / Equity	0.37x	0.68x	1.73x	-	-	0.06x	0.06x	0.08x	0.14x	-
Interest Coverage	-16.99x	-20.90x	-12.55x	-7.47x	-5.03x	-4.89x	-9.41x	-11.11x	-23.94x	-72.43x
FCF Conversion	0.51x	0.59x	0.91x	0.92x	0.82x	0.86x	0.83x	0.96x	0.81x	0.91x
Revenue Growth	-19.96%	-4.46%	31.5%	5.35%	-4.07%	8.31%	-1.72%	-4.57%	-1.37%	8.83%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Gross Royalty Revenue	-	-	-	-	10.4M	-	-	10.28M	9.9M	10.9M
Gross Royalty Revenue Growth	-	-	-	-	-	-	-	-	-3.68%	10.10%
Other Revenue	-	-	-	-	-	214K	1K	-	-	-
Other Revenue Growth	-	-	-	-	-	-	-99.53%	-	-	-
Contra Revenue	-	-	-	-	-	-103K	-101K	-116K	-	-
Contra Revenue Growth	-	-	-	-	-	-	1.94%	-14.85%	-	-
Royalty	-	-	-	10.42M	-	10.72M	10.75M	-	-	-
Royalty Growth	-	-	-	-	-	-	0.23%	-	-	-
Research And Development, Net	-	-	-	-	100K	-	-	-	-	-
Research And Development, Net Growth	-	-	-	-	-	-	-	-	-	-
Reimbursable Research and Development Adjustment	-	-	-	7K	-	-	-	-	-	-
Reimbursable Research and Development Adjustment Growth	-	-	-	-	-	-	-	-	-	-
Drug Development Royalty	696.85K	700K	200K	-	-	-	-	-	-	-
Drug Development Royalty Growth	-	0.45%	-71.43%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Curis, Inc. (CRIS) reported $11.7M in revenue for fiscal year 2024. This represents a 21% decrease from $14.8M in 2011.

Curis, Inc. (CRIS) grew revenue by 8.8% over the past year. This is steady growth.

Curis, Inc. (CRIS) reported a net loss of $36.6M for fiscal year 2024.

Dividend & Returns

Curis, Inc. (CRIS) has a return on equity (ROE) of -634.7%. Negative ROE indicates the company is unprofitable.

Curis, Inc. (CRIS) had negative free cash flow of $30.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Curis, Inc. (CRIS) 10-Year Financial Performance & Capital Metrics

CRIS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $11M +8.8%
EBITDA -$44M +7.8%
Net Income -$43M +8.5%
EPS (Diluted) -6.88 +23.2%
Gross Margin 99.1% +1.2%
EBITDA Margin -406.48% +15.3%
Operating Margin -408.34% +15.3%
Net Margin -397.77% +15.9%
ROE -634.71% -343.3%
ROIC -
Debt/Equity -
Interest Coverage -72.43 -202.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 19.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.03%

5Y1.75%

3Y0.8%

TTM13.56%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM53.07%

ROCE

10Y Avg-66.65%

5Y Avg-53.47%

3Y Avg-73.5%

Latest-114.95%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.88M	7.53M	9.9M	10.43M	10M	10.84M	10.65M	10.16M	10.02M	10.91M
Revenue Growth %	-0.2%	-0.04%	0.31%	0.05%	-0.04%	0.08%	-0.02%	-0.05%	-0.01%	0.09%
Cost of Goods Sold+	405.76K	399K	496K	563K	503K	534K	533K	257K	212K	98K
COGS % of Revenue	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%	0.03%	0.02%	0.01%
Gross Profit+	7.47M	7.13M	9.4M	9.87M	9.5M	10.3M	10.12M	9.9M	9.81M	10.81M
Gross Margin %	0.95%	0.95%	0.95%	0.95%	0.95%	0.95%	0.95%	0.97%	0.98%	0.99%
Gross Profit Growth %	-0.21%	-0.05%	0.32%	0.05%	-0.04%	0.08%	-0.02%	-0.02%	-0.01%	0.1%
Operating Expenses+	39.61M	47.18M	59.16M	39.2M	33.86M	35.2M	52.18M	62.92M	58.14M	55.35M
OpEx % of Revenue	5.03%	6.27%	5.98%	3.76%	3.38%	3.25%	4.9%	6.19%	5.8%	5.07%
Selling, General & Admin	12.91M	15.59M	25.82M	14.79M	11.55M	12.13M	17.3M	19.65M	18.65M	16.79M
SG&A % of Revenue	1.64%	2.07%	2.61%	1.42%	1.16%	1.12%	1.62%	1.93%	1.86%	1.54%
Research & Development	26.7M	31.59M	33.34M	24.41M	22.3M	23.07M	34.88M	43.28M	39.5M	38.56M
R&D % of Revenue	3.39%	4.2%	3.37%	2.34%	2.23%	2.13%	3.28%	4.26%	3.94%	3.54%
Other Operating Expenses	0	-1K	-104K	0	0	0	0	0	0	0
Operating Income+	-56.48M	-58.04M	-49.76M	-29.33M	-24.36M	-24.9M	-42.06M	-53.02M	-48.33M	-44.54M
Operating Margin %	-7.17%	-7.71%	-5.03%	-2.81%	-2.43%	-2.3%	-3.95%	-5.22%	-4.82%	-4.08%
Operating Income Growth %	-2.56%	-0.03%	0.14%	0.41%	0.17%	-0.02%	-0.69%	-0.26%	0.09%	0.08%
EBITDA+	-56.32M	-57.85M	-49.52M	-29.16M	-24.23M	-24.75M	-41.91M	-52.79M	-48.08M	-44.34M
EBITDA Margin %	-7.15%	-7.69%	-5%	-2.8%	-2.42%	-2.28%	-3.94%	-5.19%	-4.8%	-4.06%
EBITDA Growth %	-2.59%	-0.03%	0.14%	0.41%	0.17%	-0.02%	-0.69%	-0.26%	0.09%	0.08%
D&A (Non-Cash Add-back)	160.81K	193K	235K	177K	125K	144K	158K	233K	255K	203K
EBIT	-55.66M	-57.63M	-49.35M	-28.65M	-27.3M	-24.81M	-40.96M	-51.9M	-45.39M	-42.77M
Net Interest Income+	-3.05M	-2.37M	-3.45M	-3.24M	-4.23M	-5.03M	-4.26M	-3.65M	919K	1.15M
Interest Income	824.85K	405K	513K	684K	614K	63K	211K	1.12M	2.94M	1.77M
Interest Expense	3.33M	2.78M	3.97M	3.93M	4.85M	5.09M	4.47M	4.77M	2.02M	615K
Other Income/Expense	-26.85M	-2.37M	-3.56M	-3.24M	-7.79M	-5.01M	-3.37M	-3.65M	919K	1.15M
Pretax Income+	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Pretax Margin %	-7.49%	-8.03%	-5.39%	-3.12%	-3.21%	-2.76%	-4.27%	-5.58%	-4.73%	-3.98%
Income Tax+	3.16M	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Net Margin %	-7.49%	-8.03%	-5.39%	-3.12%	-3.21%	-2.76%	-4.27%	-5.58%	-4.73%	-3.98%
Net Income Growth %	-2.15%	-0.02%	0.12%	0.39%	0.01%	0.07%	-0.52%	-0.25%	0.16%	0.08%
Net Income (Continuing)	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-47.81	-45.50	-35.75	-19.67	-19.37	-12.29	-9.92	-12.14	-8.96	-6.88
EPS Growth %	-1.2%	0.05%	0.21%	0.45%	0.02%	0.37%	0.19%	-0.22%	0.26%	0.23%
EPS (Basic)	-47.81	-45.50	-35.75	-19.67	-19.37	-12.29	-9.92	-12.14	-8.96	-6.88
Diluted Shares Outstanding	1.23M	1.33M	1.49M	1.66M	1.66M	2.43M	4.58M	4.67M	5.29M	6.31M
Basic Shares Outstanding	1.23M	1.33M	1.49M	1.66M	1.66M	2.43M	4.58M	4.67M	5.29M	6.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	84.3M	46.94M	64.29M	27.13M	25M	172.75M	122.38M	92.12M	60.91M	26.39M
Cash & Short-Term Investments	82.19M	44.48M	60.23M	24.27M	20.54M	168.49M	115.88M	85.62M	56.33M	20M
Cash Only	33.09M	26.04M	38.29M	23.64M	15.43M	129.61M	40.01M	19.66M	26.68M	20M
Short-Term Investments	49.1M	18.45M	21.94M	634K	5.11M	38.88M	75.87M	65.97M	29.65M	0
Accounts Receivable	2.11M	2.46M	3.07M	2.86M	3.24M	3.04M	3.22M	2.98M	2.79M	3.35M
Days Sales Outstanding	97.57	119.24	113.32	100.25	118.36	102.51	110.5	106.86	101.75	112.06
Inventory	-1.2M	-1.26M	0	-827K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	153K	0	0	3.52M	1.78M	3.04M
Total Non-Current Assets+	10.67M	10.81M	9.5M	10.23M	10.1M	31.61M	39.93M	16.73M	16.37M	14.88M
Property, Plant & Equipment	277.71K	413K	366K	267K	303K	7.24M	6.25M	5.09M	3.49M	3.39M
Fixed Asset Turnover	28.37x	18.23x	27.04x	39.06x	33.02x	1.50x	1.70x	2.00x	2.87x	3.21x
Goodwill	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M	8.98M
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	152.61K	153K	153K	153K	0	14.56M	23.96M	0	0	544K
Other Non-Current Assets	1.41M	1.41M	156K	982K	819K	819K	726K	2.66M	3.9M	1.96M
Total Assets+	94.97M	57.75M	73.8M	37.37M	35.11M	204.36M	162.3M	108.85M	77.28M	41.27M
Asset Turnover	0.08x	0.13x	0.13x	0.28x	0.28x	0.05x	0.07x	0.09x	0.13x	0.26x
Asset Growth %	0.52%	-0.39%	0.28%	-0.49%	-0.06%	4.82%	-0.21%	-0.33%	-0.29%	-0.47%
Total Current Liabilities+	6.29M	8.63M	14.1M	6.38M	6.54M	10.08M	13.44M	10.01M	22.02M	19.03M
Accounts Payable	4.22M	5.88M	5.42M	2.91M	4.46M	4.17M	6.42M	3.19M	3.17M	3.02M
Days Payables Outstanding	3.79K	5.38K	3.99K	1.89K	3.24K	2.85K	4.39K	4.53K	5.46K	11.26K
Short-Term Debt	4.61M	4.94M	5.89M	6.88M	0	557K	0	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	-3.16M	2.03M	606K	683K	1.41M	2.64M	3.26M	0	8.5M	7.56M
Current Ratio	13.40x	5.44x	4.56x	4.25x	3.82x	17.14x	9.11x	9.20x	2.77x	1.39x
Quick Ratio	13.59x	5.59x	4.56x	4.38x	3.82x	17.14x	9.11x	9.20x	2.77x	1.39x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	24.16M	19.86M	35.7M	35.48M	62.48M	63.61M	58.16M	52.28M	35.59M	28.24M
Long-Term Debt	19.56M	14.92M	35.67M	28.6M	0	334K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	5.04M	4.36M	2.8M	1.49M	1.62M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.61M	18K	34K	11K	62.48M	58.23M	53.8M	49.48M	34.1M	26.62M
Total Liabilities	30.45M	28.49M	49.8M	41.86M	69.02M	73.69M	71.59M	62.3M	57.61M	47.26M
Total Debt+	24.16M	19.86M	41.55M	35.48M	166K	7.66M	5.04M	3.94M	2.79M	2.95M
Net Debt	-8.93M	-6.18M	3.27M	11.85M	-15.26M	-121.95M	-34.97M	-15.72M	-23.89M	-17.04M
Debt / Equity	0.37x	0.68x	1.73x	-	-	0.06x	0.06x	0.08x	0.14x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.99x	-20.90x	-12.55x	-7.47x	-5.03x	-4.89x	-9.41x	-11.11x	-23.94x	-72.43x
Total Equity+	64.51M	29.27M	23.99M	-4.5M	-33.91M	130.67M	90.71M	46.55M	19.67M	-6M
Equity Growth %	1.17%	-0.55%	-0.18%	-1.19%	-6.54%	4.85%	-0.31%	-0.49%	-0.58%	-1.3%
Book Value per Share	52.29	22.04	16.09	-2.72	-20.44	53.70	19.81	9.97	3.72	-0.95
Total Shareholders' Equity	64.51M	29.27M	23.99M	-4.5M	-33.91M	130.67M	90.71M	46.55M	19.67M	-6M
Common Stock	1.3M	1.42M	1.65M	332K	332K	915K	916K	48K	59K	85K
Retained Earnings	-838.54M	-898.95M	-952.26M	-984.84M	-1.02B	-1.05B	-1.09B	-1.15B	-1.2B	-1.24B
Treasury Stock	-1.52M	-1.52M	-1.52M	0	0	0	0	0	0	0
Accumulated OCI	27.77K	-4K	-2K	0	0	-3K	-109K	-186K	229K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.89M	-35.81M	-48.35M	-30.07M	-26.2M	-25.74M	-37.62M	-54.34M	-38.43M	-39.56M
Operating CF Margin %	-3.79%	-4.76%	-4.89%	-2.88%	-2.62%	-2.38%	-3.53%	-5.35%	-3.83%	-3.63%
Operating CF Growth %	-0.78%	-0.2%	-0.35%	0.38%	0.13%	0.02%	-0.46%	-0.44%	0.29%	-0.03%
Net Income	-58.98M	-60.41M	-53.32M	-32.58M	-32.14M	-29.91M	-45.44M	-56.67M	-47.41M	-43.39M
Depreciation & Amortization	160.81K	193K	235K	177K	125K	144K	158K	1.39M	255K	187K
Stock-Based Compensation	3.88M	4.33M	5.36M	3.94M	0	2.7M	5.28M	0	6M	5.93M
Deferred Taxes	-21.55K	0	0	7K	0	24K	1.4M	0	0	0
Other Non-Cash Items	24.17M	18.2M	91K	-112K	7.37M	255K	-26K	7.76M	-55K	1.43M
Working Capital Changes	903.59K	1.88M	-723K	-1.5M	-1.56M	1.05M	1M	-6.82M	2.78M	-3.72M
Change in Receivables	-145.04K	-353K	-614K	209K	-380K	201K	-181K	249K	181K	-555K
Change in Inventory	-75.47M	-34.74M	-49.92M	1.87M	0	0	0	0	0	0
Change in Payables	1.77M	2.31M	-376K	-1.87M	60K	1M	4.96M	-3.88M	3.34M	-2.08M
Cash from Investing+	-6.43M	30.12M	-3.63M	21.37M	-4.46M	-49.05M	-47.9M	33.02M	37.79M	29.44M
Capital Expenditures	-47.98K	-329K	-188K	-85K	-41K	-677K	0	-416K	0	0
CapEx % of Revenue	0.01%	0.04%	0.02%	0.01%	0%	0.06%	-	0.04%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	13.88K	-329K	-188K	-85K	0	0	0	0	0	0
Cash from Financing+	61.66M	-1.37M	64.23M	-5.96M	23.27M	188.81M	-4.17M	867K	7.58M	3.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	946K	143K	0	-5.3M	-4.47M	0	-6.54M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-29.94M	-36.14M	-48.54M	-30.15M	-26.25M	-26.42M	-37.62M	-54.75M	-38.43M	-39.56M
FCF Margin %	-3.8%	-4.8%	-4.9%	-2.89%	-2.62%	-2.44%	-3.53%	-5.39%	-3.83%	-3.63%
FCF Growth %	-0.77%	-0.21%	-0.34%	0.38%	0.13%	-0.01%	-0.42%	-0.46%	0.3%	-0.03%
FCF per Share	-24.27	-27.22	-32.55	-18.21	-15.82	-10.86	-8.22	-11.73	-7.26	-6.27
FCF Conversion (FCF/Net Income)	0.51x	0.59x	0.91x	0.92x	0.82x	0.86x	0.83x	0.96x	0.81x	0.91x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-125.1%	-128.84%	-200.22%	-334.15%	-	-61.82%	-41.05%	-82.58%	-143.19%	-634.71%
Return on Invested Capital (ROIC)	-79.99%	-110.66%	-148.25%	-127.12%	-	-	-97.89%	-91.87%	-272.36%	-
Gross Margin	94.85%	94.7%	94.99%	94.6%	94.97%	95.07%	94.99%	97.47%	97.88%	99.1%
Net Margin	-748.64%	-802.59%	-538.66%	-312.38%	-321.28%	-276.03%	-426.67%	-557.69%	-473.04%	-397.77%
Debt / Equity	0.37x	0.68x	1.73x	-	-	0.06x	0.06x	0.08x	0.14x	-
Interest Coverage	-16.99x	-20.90x	-12.55x	-7.47x	-5.03x	-4.89x	-9.41x	-11.11x	-23.94x	-72.43x
FCF Conversion	0.51x	0.59x	0.91x	0.92x	0.82x	0.86x	0.83x	0.96x	0.81x	0.91x
Revenue Growth	-19.96%	-4.46%	31.5%	5.35%	-4.07%	8.31%	-1.72%	-4.57%	-1.37%	8.83%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Gross Royalty Revenue	-	-	-	-	10.4M	-	-	10.28M	9.9M	10.9M
Gross Royalty Revenue Growth	-	-	-	-	-	-	-	-	-3.68%	10.10%
Other Revenue	-	-	-	-	-	214K	1K	-	-	-
Other Revenue Growth	-	-	-	-	-	-	-99.53%	-	-	-
Contra Revenue	-	-	-	-	-	-103K	-101K	-116K	-	-
Contra Revenue Growth	-	-	-	-	-	-	1.94%	-14.85%	-	-
Royalty	-	-	-	10.42M	-	10.72M	10.75M	-	-	-
Royalty Growth	-	-	-	-	-	-	0.23%	-	-	-
Research And Development, Net	-	-	-	-	100K	-	-	-	-	-
Research And Development, Net Growth	-	-	-	-	-	-	-	-	-	-
Reimbursable Research and Development Adjustment	-	-	-	7K	-	-	-	-	-	-
Reimbursable Research and Development Adjustment Growth	-	-	-	-	-	-	-	-	-	-
Drug Development Royalty	696.85K	700K	200K	-	-	-	-	-	-	-
Drug Development Royalty Growth	-	0.45%	-71.43%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Curis, Inc. (CRIS) reported $11.7M in revenue for fiscal year 2024. This represents a 21% decrease from $14.8M in 2011.

Curis, Inc. (CRIS) grew revenue by 8.8% over the past year. This is steady growth.

Curis, Inc. (CRIS) reported a net loss of $36.6M for fiscal year 2024.

Dividend & Returns

Curis, Inc. (CRIS) has a return on equity (ROE) of -634.7%. Negative ROE indicates the company is unprofitable.

Curis, Inc. (CRIS) had negative free cash flow of $30.1M in fiscal year 2024, likely due to heavy capital investments.